CGRP Migraine Drugs May Also Cause Raynaud's Phenomenon: A New Safety Signal from FDA Data
Data mining of the FDA adverse event database identified Raynaud's phenomenon as a novel safety signal associated with all CGRP antagonists, with network pharmacology suggesting involvement of IGF1R pathways.
Quick Facts
What This Study Found
Raynaud's phenomenon was identified as a novel safety signal for all CGRP antagonists using FAERS data mining (PRR ≥2, chi-square ≥4, ROR lower 95% CI >2), with IGF1R pathway involvement suggested by network pharmacology.
Key Numbers
Data covered reports from 2004 Q1 to 2022 Q3 in the US FAERS database.
How They Did This
Data mining of FDA FAERS database (2004 Q1 - 2022 Q3) using reporting odds ratio and proportional reporting ratio algorithms. Network pharmacology using Cytoscape 3.7.2 and molecular docking with Glide (Schrödinger) to explore mechanistic pathways.
Why This Research Matters
CGRP is a powerful vasodilator, so blocking it could theoretically constrict blood vessels. This signal confirms that concern. Patients with pre-existing Raynaud's or vascular conditions should be monitored when starting CGRP antagonists for migraine.
The Bigger Picture
As CGRP antagonists become widely prescribed for migraine prevention, understanding their vascular side effects becomes increasingly important. CGRP's role in maintaining blood vessel dilation means blocking it could have consequences for peripheral circulation, particularly in susceptible individuals.
What This Study Doesn't Tell Us
FAERS data mining identifies signals but cannot establish causation. Reporting bias is inherent in adverse event databases. The IGF1R pathway involvement is computational prediction, not experimentally validated. The actual incidence of Raynaud's with CGRP drugs cannot be determined from this analysis.
Questions This Raises
- ?Should patients with pre-existing Raynaud's avoid CGRP antagonists or be monitored more closely?
- ?Is the Raynaud's risk different between CGRP ligand blockers and CGRP receptor blockers?
- ?Does the IGF1R mechanism offer a target for preventing this vascular side effect?
Trust & Context
- Key Stat:
- Novel Raynaud's signal detected All CGRP antagonists showed statistically significant association with Raynaud's phenomenon in FDA FAERS data
- Evidence Grade:
- Preliminary evidence from pharmacovigilance data mining and computational analysis. Establishes a safety signal requiring clinical investigation.
- Study Age:
- Published in 2024. Relevant as CGRP antagonist prescriptions continue to grow rapidly.
- Original Title:
- Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches.
- Published In:
- Expert opinion on drug safety, 23(2), 231-238 (2024)
- Authors:
- Singh, Rima, Kumar, Anoop, Lather, Viney, Sharma, Ruchika, Pandita, Deepti
- Database ID:
- RPEP-09279
Evidence Hierarchy
Frequently Asked Questions
What is Raynaud's phenomenon and why might CGRP drugs cause it?
Raynaud's phenomenon causes blood vessel spasms in the extremities (usually fingers and toes), leading to pain, numbness, and color changes. CGRP is a powerful blood vessel dilator, so blocking it with migraine drugs could reduce blood flow to the extremities, potentially triggering Raynaud's in susceptible people.
Should I stop my CGRP migraine medication if I have cold fingers?
Don't stop medication without talking to your doctor. While this study identifies a potential link between CGRP drugs and Raynaud's, the actual risk appears low. If you experience persistent cold, painful, or discolored fingers or toes, discuss this with your prescriber.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09279APA
Singh, Rima; Kumar, Anoop; Lather, Viney; Sharma, Ruchika; Pandita, Deepti. (2024). Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches.. Expert opinion on drug safety, 23(2), 231-238. https://doi.org/10.1080/14740338.2023.2248877
MLA
Singh, Rima, et al. "Identification of novel signal of Raynaud's phenomenon with Calcitonin Gene-Related Peptide(CGRP) antagonists using data mining algorithms and network pharmacological approaches.." Expert opinion on drug safety, 2024. https://doi.org/10.1080/14740338.2023.2248877
RethinkPeptides
RethinkPeptides Research Database. "Identification of novel signal of Raynaud's phenomenon with ..." RPEP-09279. Retrieved from https://rethinkpeptides.com/research/singh-2024-identification-of-novel-signal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.